Hepatocellular carcinoma in HIV-infected patients: Check early, treat hard

Oncologist

Volumn 16, Issue 9, 2011, Pages 1258-1269

  Berretta, Massimiliano ^a   Garlassi, Elisa ^b   Cacopardo, Bruno ^c   Cappellani, Alessandro ^c   Guaraldi, Giovanni ^b   Cocchi, Stefania ^b   de Paoli, Paolo ^a   Lleshi, Arben ^a   Izzi, Immacolata ^d   Torresin, Augusta ^e   di Gangi, Pietro ^b   Pietrangelo, Antonello ^b   Ferrari, Mariachiara ^b   Bearz, Alessandra ^a   Berretta, Salvatore ^c   Nasti, Guglielmo ^f   di Benedetto, Fabrizio ^b   Balestreri, Luca ^a   Tirelli, Umberto ^a   Ventura, Paolo ^b  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY OF CATANIA   (Italy)

^d CATHOLIC UNIVERSITY   (Italy)

^e GALLIERA HOSPITAL   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

AIDS; Hepatitis C virus; Hepatocellular carcinoma; Highly active antiretroviral therapy; HIV

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SORAFENIB;

ARTICLE; CANCER RECURRENCE; CANCER RELAPSE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CD4 LYMPHOCYTE COUNT; CHEMOEMBOLIZATION; CHRONIC LIVER DISEASE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOPPLER FLOWMETRY; FEMALE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER CELL CARCINOMA; LIVER SURGERY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PORTAL VEIN THROMBOSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SURVIVAL TIME; TUMOR VOLUME; VIRUS LOAD;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, HEPATOCELLULAR; FEMALE; HIV; HIV INFECTIONS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 80053187997     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2010-0400     Document Type: Article

References (43)

1. UNAIDS: Global Summary of the HIV and AIDS Epidemic. Available at http://www.unaids.org, 2007.
2. Murphy EL, Collier AC, Kalish LA et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 2001;135:17-26.
3. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338: 853-860.
4. Bica I, McGovern B, Dhar R et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001;32:492-497.
5. Macías J, Melguizo I, Fernàndez-Rivera FJ et al. Mortality due to liver failure and impact on survival of hepatitis virus infections in HIV-infected patients receiving potent antiretroviral therapy. Eur J Clin Microbiol Infect Dis 2002;21:775-781.
6. Koziel MJ, Peters MG. Viral hepatitis in HIV infection. NEnglJ Med 2007; 356:1445-1454.
7. Sulkowski MS, Thomas DL, Chaisson RE et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283:74-80.
8. Sulkowski MS. Viral hepatitis and HIV coinfection. J Hepatol 2008;48: 353-367.
9. Deuffic-Burban S, Poynard T, Sulkowski MS et al. Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States. J Viral Hepat 2007;14:107-115.
10. Gomaa AI, Khan SA, Toledano MB et al. Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008;14: 4300-4308.
11. Bosch FX, Ribes J, Diaz M et al. Primary liver cancer: Worldwide incidence and trends. Gastroenterology 2004;127(suppl 1):S5-S16.
12. Jong-wook L. Global health improvement and WHO: Shaping the future. Lancet 2003;362:2083-2088.
13. Clifford GM, Rickenbach M, Polesel J et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS 2008;22: 2135-2141.
14. Smukler AJ, Ratner L. Hepatitis viruses and hepatocellular carcinoma in HIV-infected patients. Curr Opin Oncol 2002;14:538-542.
15. Lewden C, Salmon D, Morlat P et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretro-viral therapy: Emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol 2005;34:121-130.
16. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatol-ogy 2005;42:1208-1236.
17. El-Serag HB, Marrero JA, Rudolph L et al. Diagnosis and treatment of hep-atocellular carcinoma. Gastroenterology 2008;134:1752-1763.
18. Thio CL, Seaberg EC, Skolasky R Jr et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 2002;360:1921-1926.
19. Salmon D, Robain M, Rockstroh JK et al. Therapeutic management of hepatitis and HIV infection in co-infected patients: Results of a survey performed before the 2005 Consensus Conference. J Hepatol 2006;44(1 suppl):S2-S5.
20. Giordano TP, Kramer JR, Souchek J et al. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: A cohort study, 1992-2001. Arch Intern Med 2004;164:2349-2354.
21. Pineda JA, Romero-Gómez M, Díaz-García F et al. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005;41:779-789.
22. Reisler K. High hepatotoxicity rate seen among HAART patients. AIDS Alert 2001;16:118-119.
23. Puoti M, Bruno R, Soriano V et al. Hepatocellular carcinoma in HIV-infected patients: Epidemiological features, clinical presentation and outcome. AIDS 2004;18:2285-2293.
24. Bräu N, Fox RK, Xiao P et al. Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: A U.S.-Canadian multicenter study. J Hepatol 2007;47:527-537.
25. García-Samaniego J, Rodríguez M, Berenguer J et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroen-terol 2001;96:179-183.
26. Bruno R, Sacchi P, Filice C et al. Hepatocellular carcinomain HIV-infected patients with chronic hepatitis: An emerging issue. J Acquir Immune Defic Syndr 2002;30:535-536.
27. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: The BCLC staging classification. Semin Liver Dis 1999;19:329-338.
28. Marrero JA, Fontana RJ, Barrat A et al. Prognosis of hepatocellular carcinoma: Comparison of7staging systems inanAmerican cohort. Hepatology 2005;41:707-716.
29. Hosmer DW, Lemeshow SS. Applied Logistic Regression. 2nd ed. Hobo-ken, NJ: Wiley, 2000:1-392.
30. Colombo M. Screening and diagnosis of hepatocellular carcinoma. Liver Int 2009;29(suppl 1):143-147.
31. Pascual S, Irurzun J, Zapater P et al. Usefulness of surveillance programmes for early diagnosis of hepatocellular carcinoma in clinical practice. Liver Int 2008;28:682-689.
32. Salmon-Ceron D, Rosenthal E, Lewden C et al. Emerging role of hepato-cellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study. J Hepatol 2009;50: 736-745.
33. Miailhes P, Trabaud MA, Pradat P et al. Impact of highly active antiretro-viral therapy (HAART) on the natural history of hepatitis B virus (HBV) and HIV coinfection: Relationship between prolonged efficacy of HAART and HBV surface and early antigen seroconversion. Clin Infect Dis 2007; 45:624-632.
34. Asmuth DM, Busch MP, Laycock ME et al. Hepatitis B and C viral load changes following initiation of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection. Antiviral Res 2004;63: 123-131.
35. Vogel M, Rockstroh JK. Liver disease: The effects of HIV and antiretrovi-ral therapy and the implications for early antiretroviral therapy initiation. Curr Opin HIV AIDS 2009;4:171-175.
36. Di Benedetto F, De Ruvo N, Berretta M et al. Don't deny liver transplantation to HIV patients with hepatocellular carcinoma in the highly active antiretroviral therapy era. J Clin Oncol 2006;24:e26-e27.
37. Di Benedetto F, De Ruvo N, Berretta M et al. Hepatocellular carcinoma in HIV patients treated by liver transplantation. Eur J Surg Oncol 2008;34: 422-427.
38. Takaki H, Yamakado K, Nakatsuka A et al. Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas 5 cm or smaller: Risk factors for local tumor progression. J Vasc Interv Radiol 2007;18:856-861.
39. Ventura P, De Santis M, Romagnoli E et al. Radiofrequency ablation combined with transcatheter chemoembolization in the treatment of advanced hepatocellular carcinoma. Gut 2008;57(suppl II):A153.
40. Bruno R, Puoti M, Sacchi P et al. Management of hepatocellular carcinoma in human immunodeficiency virus-infected patients. J Hepatol 2006;44(1 suppl):S146-S150.
41. Bruix J, Sherman M, Llovet JM et al. Clinical management of hepatocel-lular carcinoma. Conclusionsof the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 2001;35:421-430.
42. Hoofnagle JH. Hepatocellular carcinoma: Summary and recommendations. Gastroenterology 2004;127(suppl 1):S319-S323.
43. Management of hepatocellular carcinoma: From prevention to molecular targeted therapy. Proceedings of the 3rd International Kobe Liver Symposium on HCC with an International Liver Cancer Association (ILCA) Scientific Session. Hyogo, Japan, June 6-7, 2009. Oncology 2010;78(suppl 1):1-190.